search
Back to results

Concomitant Radio-chemotherapy in the Elderly (RACCOSA)

Primary Purpose

Non Small Cell Lung Cancer

Status
Completed
Phase
Phase 2
Locations
France
Study Type
Interventional
Intervention
Cisplatin IV
Vinorelbine
Radiotherapy
Sponsored by
University Hospital, Limoges
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Non Small Cell Lung Cancer focused on measuring Locally advanced lung cancer, Elderly patients, NSCLC

Eligibility Criteria

70 Years - undefined (Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age ≥ 70 years
  • Independent patients (based on the score of geriatric frailty: IADL = 0, ADL = 0, no geriatric syndrome, low comorbidity (comorbidity index of Charlson to 3 or 4), depression score 0-1)
  • Performance Status (ECOG) ≤ 1
  • Weight loss <10% of usual weight in the last 3 months
  • Life expectancy greater than 12 weeks
  • Hematologic function: neutrophils> 1.5 x 10**9 / l, hemoglobin> 9.5 g / dl, platelets > 100 x 10**9 / l)
  • Renal function: creatinine clearance ≥ 50 ml / min calculated by the formula of MDRD
  • Normal liver function: bilirubin < Limit of Normal (ULN), SGOT and / or SGPT <2.5 x UNL
  • Respiratory Function: FEV ≥ 40% predicted, PaO2 ≥ 60 mm Hg, KCO ≥ 60% predicted
  • Patient affiliated to a social security regimen or beneficiary of such regimen
  • Informed consent signed

The disease

  • Pathological anatomy: CBP non-small cell (squamous cell carcinoma, adenocarcinoma, large cell carcinoma, undifferentiated carcinoma) histologically or cytologically proven
  • Stage IIIAN2 considered inoperable stage IIIB
  • Presence of at least one measurable target
  • Delay at least three weeks between surgery and initiation of treatment
  • No prior treatment with chemotherapy or radiotherapy for lung cancer

Exclusion Criteria:

  • Age < 70 years
  • Performance Status (ECOG) ≥ 2
  • Hematologic function: neutrophils <1.5 x 10**9 / l, hemoglobin <9.5 g / dl, platelets <100 x 10**9 / l)
  • Renal function: creatinine clearance <50 ml / min calculated by the formula of MDRD
  • Hepatic: bilirubin> Upper Limit of Normal (ULN), SGOT and / or SGPT> 2.5 x ULN
  • Respiratory Function: FEV <40% predicted, KCO <60% predicted, PaO2 <60 mmHg
  • Peripheral neuropathy grade> 1
  • Unstable cardiac pathology requiring treatment (heart failure, angor of effort, arrhythmia) or previous myocardial infarction older than 12 months
  • Deafness not paired or deafness requiring major achievement of an audiogram-cons may indicate taking cisplatin
  • Neurological or psychiatric disorders prohibiting the understanding of the test
  • Previous history of cancer except basal cell cancer, carcinoma in situ of the cervix treated or any other cancer treated with surgery alone or radiotherapy alone extra-thoracic recurrence-free 5 years
  • Significant malabsorption syndrome or disease affecting the functioning of the gastrointestinal tract

The disease

  • Pathological anatomy: Bronchioloalveolar carcinoma, neuroendocrine carcinoma, small cell carcinoma
  • Metastatic disease
  • Pleural drain
  • Carcinomatous lymphangitis
  • Operable Cancer
  • Previously treated for lung cancer disease: radiotherapy, chemotherapy, hormonal therapy, endobronchial suctioning older less than eight days

Sites / Locations

  • CHU Brest
  • Centre Hospitalier GAP
  • Département de Pathologie Respiratoire du CHU de Limoges
  • CH de Meaux
  • CHU Reims

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

experimental

Arm Description

Outcomes

Primary Outcome Measures

Acute toxicity

Secondary Outcome Measures

Late toxicity
Overall response rate

Full Information

First Posted
December 9, 2009
Last Updated
May 1, 2018
Sponsor
University Hospital, Limoges
Collaborators
Pierre Fabre Laboratories
search

1. Study Identification

Unique Protocol Identification Number
NCT01029678
Brief Title
Concomitant Radio-chemotherapy in the Elderly
Acronym
RACCOSA
Official Title
Phase II Study Evaluating Treatment With Oral Navelbine and Cisplatin Administered Weekly and Concomitant Radiotherapy in Elderly Patients With no Operable NSCLC
Study Type
Interventional

2. Study Status

Record Verification Date
January 2018
Overall Recruitment Status
Completed
Study Start Date
January 2010 (undefined)
Primary Completion Date
January 2015 (Actual)
Study Completion Date
June 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Limoges
Collaborators
Pierre Fabre Laboratories

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to evaluate the safety of non small cell lung cancer (NSCLC) treatment with cisplatin and oral vinorelbine administered weekly associated with concomitant radiotherapy in elderly patients.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Non Small Cell Lung Cancer
Keywords
Locally advanced lung cancer, Elderly patients, NSCLC

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
48 (Actual)

8. Arms, Groups, and Interventions

Arm Title
experimental
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
Cisplatin IV
Intervention Description
Cisplatin IV 30 mg/m2/ (Day 1, Day 8, Day 15, Day 22, Day 29, Day 36)
Intervention Type
Drug
Intervention Name(s)
Vinorelbine
Intervention Description
Vinorelbine per os 30 mg/m2/(day1, day8, day15, day22, day29, day36
Intervention Type
Radiation
Intervention Name(s)
Radiotherapy
Intervention Description
66Gy, 33 fractions, 6 week
Primary Outcome Measure Information:
Title
Acute toxicity
Time Frame
during treatment and during the 4 weeks following the end of treatment
Secondary Outcome Measure Information:
Title
Late toxicity
Time Frame
6 months after the end of the treatment
Title
Overall response rate
Time Frame
4 weeks after treatment

10. Eligibility

Sex
All
Minimum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age ≥ 70 years Independent patients (based on the score of geriatric frailty: IADL = 0, ADL = 0, no geriatric syndrome, low comorbidity (comorbidity index of Charlson to 3 or 4), depression score 0-1) Performance Status (ECOG) ≤ 1 Weight loss <10% of usual weight in the last 3 months Life expectancy greater than 12 weeks Hematologic function: neutrophils> 1.5 x 10**9 / l, hemoglobin> 9.5 g / dl, platelets > 100 x 10**9 / l) Renal function: creatinine clearance ≥ 50 ml / min calculated by the formula of MDRD Normal liver function: bilirubin < Limit of Normal (ULN), SGOT and / or SGPT <2.5 x UNL Respiratory Function: FEV ≥ 40% predicted, PaO2 ≥ 60 mm Hg, KCO ≥ 60% predicted Patient affiliated to a social security regimen or beneficiary of such regimen Informed consent signed The disease Pathological anatomy: CBP non-small cell (squamous cell carcinoma, adenocarcinoma, large cell carcinoma, undifferentiated carcinoma) histologically or cytologically proven Stage IIIAN2 considered inoperable stage IIIB Presence of at least one measurable target Delay at least three weeks between surgery and initiation of treatment No prior treatment with chemotherapy or radiotherapy for lung cancer Exclusion Criteria: Age < 70 years Performance Status (ECOG) ≥ 2 Hematologic function: neutrophils <1.5 x 10**9 / l, hemoglobin <9.5 g / dl, platelets <100 x 10**9 / l) Renal function: creatinine clearance <50 ml / min calculated by the formula of MDRD Hepatic: bilirubin> Upper Limit of Normal (ULN), SGOT and / or SGPT> 2.5 x ULN Respiratory Function: FEV <40% predicted, KCO <60% predicted, PaO2 <60 mmHg Peripheral neuropathy grade> 1 Unstable cardiac pathology requiring treatment (heart failure, angor of effort, arrhythmia) or previous myocardial infarction older than 12 months Deafness not paired or deafness requiring major achievement of an audiogram-cons may indicate taking cisplatin Neurological or psychiatric disorders prohibiting the understanding of the test Previous history of cancer except basal cell cancer, carcinoma in situ of the cervix treated or any other cancer treated with surgery alone or radiotherapy alone extra-thoracic recurrence-free 5 years Significant malabsorption syndrome or disease affecting the functioning of the gastrointestinal tract The disease Pathological anatomy: Bronchioloalveolar carcinoma, neuroendocrine carcinoma, small cell carcinoma Metastatic disease Pleural drain Carcinomatous lymphangitis Operable Cancer Previously treated for lung cancer disease: radiotherapy, chemotherapy, hormonal therapy, endobronchial suctioning older less than eight days
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Chrystèle LOCHER, MD
Organizational Affiliation
CH Meaux
Official's Role
Study Chair
Facility Information:
Facility Name
CHU Brest
City
Brest
Country
France
Facility Name
Centre Hospitalier GAP
City
GAP
Country
France
Facility Name
Département de Pathologie Respiratoire du CHU de Limoges
City
Limoges
Country
France
Facility Name
CH de Meaux
City
Meaux
Country
France
Facility Name
CHU Reims
City
Reims
Country
France

12. IPD Sharing Statement

Learn more about this trial

Concomitant Radio-chemotherapy in the Elderly

We'll reach out to this number within 24 hrs